Journal Information
Vol. 95. Issue 5.
Pages 368-370 (01 November 2021)
Vol. 95. Issue 5.
Pages 368-370 (01 November 2021)
Scientific Letter
Open Access
Restrictive cardiomyopathy: Importance of early diagnosis
Miocardiopatía restrictiva: la importancia de su diagnóstico precoz
Visits
...
Laia Brunet-Garciaa,b, Ferran Roses-Noguerc,d,
Corresponding author
froses@vhebron.net

Corresponding author.
, Pedro Betriánc, Joan Balcellse, Ferran Granc
a Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, United Kingdom
b Unidad de Cardiología Pediátrica, Hospital de Mataró, Mataró, Barcelona, Spain
c Unidad de Cardiología Pediátrica, Hospital Universitario Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
d Paediatric Cardiology, Royal Brompton Hospital, London, United Kingdom
e Unidad de Cuidados Intensivos Pediátricos, Hospital Universitario Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Demographic, electrocardiographic and haemodynamic characteristics of patients with restrictive cardiomyopathy.
Full Text
Dear Editor:

Restrictive cardiomyopathy (RCM) is rare in the paediatric population (incidence of 2.5%–5% of total paediatric cardiomyopathy cases).1 It is characterised by reduced diastolic volume with preserved systolic function and normal wall thickness.2 Most cases are idiopathic. Some of the known causes of RCM are genetic changes (mainly involving sarcomere protein genes) and infiltrative diseases (infrequent in children).3 There have been descriptions in the literature of pure RCM or mixed-phenotype RCM associated to hypertrabeculation (noncompaction cardiomyopathy [NCCM)) or hypertrophy.4 Medical treatment does not improve outcomes and there is rapid progression of pulmonary hypertension (PHT) and risk of sudden death.5 Therefore, performance of a heart transplant should be considered early on.

We have summarised the data as median and interquartile range (IQR).

We present a retrospective study conducted in 9 patients with RCM diagnosed in our hospital between September 2002 and September 2019. The median duration of follow-up was 95.57 months (IQR, 0.76–209.74) and the median age at diagnosis was 24.02 months (IQR, 0.00–176.03). Table 1 summarises the characteristics of the patients. All had primary cardiomyopathy except 1 patient with suspected endomyocardial fibrosis secondary to schistosomiasis.6 Six patients presented a pure RCM phenotype (median age at diagnosis, 35.99 months; IQR, 1.81–176.03) and 3 a mixed RCM/NCCM phenotype (median age at diagnosis, 0.53 meses; IQR, 0–123.30); 2 had a family history of cardiomyopathy (1 of NCCM in a first-degree relative and 1 of RCM in first-degree and second-degree relatives). Five underwent genetic testing, with negative result in 1, detection of Alström syndrome in 1 and detection of a pathogenic variant in sarcomere protein genes in 3 (in the troponin T gene [TNNT2] in 1, and in the gene encoding the myosin heavy chain beta isoform [MYH7] in 3); 6 patients (4 with pure RCM and 2 with RCM/NCCM mixed phenotype) had onset with heart failure.

Table 1.

Demographic, electrocardiographic and haemodynamic characteristics of patients with restrictive cardiomyopathy.

  Case 1  Case 2  Case 3  Case 4  Case 5  Case 6  Case 7  Case 8  Case 9 
Mean age (years)  10.5  4.0  0.05  2.0  0.15  14.6  10.3  0.08  0.5 
Sex  Female  Male  Male  Male  Male  Female  Female  Female  Male 
Type of RCM  Secondary Schisto  Primary  Primary  Primary  Primary  Primary  Primary  Primary  Primary 
Phenotype  RCM  RCM  RCM/NCCM  RCM  RCM  RCM  RCM/NCCM  RCM/NCCM  RCM 
CM FHx  No  No  No  No  Yes  No  No  No  Yes 
Genetic testing  Not done  done  Negative  done  Alström syndrome  Change in TNNT2  done  Change in MYH7  Change in MYH7 
Symptoms of HF  Yes  Yes  Yes  No  Yes  Yes  No  Yes  No 
Electrocardiogram                   
HR (bpm)  ND  87  83  84  125  75  98  103  100 
PR interval (ms)  ND  130  160  145  121  130  192  164  110 
P-wave amplitude (mV)  ND  0.6  0.4  0.4  0.2  0.5  0.4  0.4  0.4 
QRS (ms)  ND  89  90  90  65  125  90  82  98 
QRS (axis)  ND  90  10  30  67  147  20  79  117 
R amplitude, L II (mV)  ND  1.0  0.8  1.1  0.5  0.5  0.5  1.2  0.7 
QTc  ND  437  448  440  454  488  402  490  413 
Abnormal repolarization  ND  ST depression, inferolat  Inv. T-wave lateral leads  ST depression and inv. T-wave, inferolat  Inv. T-wave Lateral leads  Inv. T wave Lateral leads  No  No  Inv. T-wave anterolat. lead 
P:QRS ratio, L II  ND  0.36  0.5  0.36  0.4  0.8  0.33  0.57 
Arrythmias  FibA  AVB  VES  No  No  VT/SD  No  No  No 
Echocardiography                   
LA (z-score)  5,20  2.39  5.57  2.09  4.26  4.56  4.60  4.20  2.60 
TI (mmHg)  100  35  80  54  58  48  66  90  15 
LVEF (%)  55  55  70  54  60  69  59  50  73 
E (m/s)  ND  0.40  0.83  0.37  1.23  1.07  0.80  0.80  1.50 
A (m/s)  ND  0.58  0.32  Not done  0.27  0.29  0.36  0.70  0.30 
E/A  ND  0.69  2.60  Not done  4.50  3.69  2.22  1.10  5.00 
E/e’  ND  7.60  8.30  7.40  13.70  21.40  8.50  16.80  10.00 
Catheterization                   
mPAP (mmHg)  62  17  55  37  Not done  37  23  58  Not done 
LAP (mmHg)  21  13  28  31  Not done  25  21  26  Not done 
LVEDP (mmHg)  24  15  27  21  Not done  32  28  28  Not done 
PVRI (UW·m223  2.2  12  6.1  Not done  6.0  5.7  6.1  Not done 
Current status  HLT/Dec  HT/Alive  HT/Alive  HT/Alive  TF/Alive  Dec  TL/Alive  HT/Alive  TL/Alive 

A, A-wave (transmitral flow); anterolat, anterolateral; AFib, atrial fibrillation; AVB, atrioventricular block; bpm, beats per minute; CM FHx, family history of cardiomyopathy; E, E-wave (transmitral flow); Dec, deceased; HF, heart failure; HLT, heart-lung transplant; HR, heart rate; HT, heart transplant; inferolat, inferolateral; inv., inverted; L, lead; LA, left atrium; LAP, left atrial pressure; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricle ejection fraction; mPAP, mean pulmonary artery pressure; ND, not documented; PVRI, pulmonary vascular resistance index; QTc, corrected QT interval; RCM, restrictive cardiomyopathy; RCM/NCCM, mixed restrictive cardiomyopathy associated with hypertrabeculation; Schisto, schistosomiasis; SD, sudden death; TF, transplant-free; TI, tricuspid insufficiency; TL, transplant list; VES, ventricular extrasystoles; VT, ventricular tachycardia.

All patients for whom we could obtain electrocardiographic data (n = 9) had a high P:QRS ratio (median, 0.5 mV; IQR, 0.33–1.00) due to an increased P-wave amplitude (median, 0.40 mV; IQR, 0.20−0.60]) and a decreased QRS complex amplitude (median, 7.5 mV; IQR, 5–12). During the follow-up, 4 patients developed arrhythmias (median months from diagnosis): 1 with left hemiparesis to an episode of atrial fibrillation (36.50), 1 with frequent ventricular extrasystoles (9.30), 1 with atrioventricular block (60.65) and 1 with nonsustained ventricular tachycardia and sudden death (0.76).

Eight patients had PHT, the degree of which was estimated based on the pressure gradient measured by echocardiography at the level of the dysfunctional tricuspid valve (median, 62 mmHg; IQR, 35–100). Seven patients underwent a haemodynamic assessment (Table 1).

After a median of 7.9 years of follow-up, 3 of the patients were alive and transplant-free (Fig. 1), 5 had undergone a transplant and 1 died suddenly while on the transplant waiting list (case 6); 4 patients underwent transplantation at a median of 61.37 months post diagnosis (IQR, 39.72–141.04). The reason for transplantation was severe bilateral ventricular failure in 1 patient (case 2) that required venoarterial extracorporeal membrane oxygenation and later biventricular support before transplantation. In 3 patients (cases 3, 4 and 8), the indication for transplantation was severe PHT and heart failure. Case 3 had suprasystemic pulmonary pressures and a pulmonary vascular resistance index (PVRI) of 12 WU·m2, leading to initiation of left ventricular support to reduce pulmonary resistance before adding the patient to the heart transplant waiting list at 4 weeks (PVRI, 3.4 WU·m2) and preforming the transplantation after 11 months of circulatory support. Case 1 had been referred from another hospital and the evaluation at admission revealed severe and irreversible PHT (mean pulmonary artery pressure [mPAP], 62 mmHg; PVRI, 23 WU·m2), so the patient underwent a heart-lung transplant. All patients survived at 4 years from transplantation. Case 1 died at 4.4 years post transplantation due to chronic rejection of the lung transplant.

Figure 1.

Patients free of sudden death/heart transplant or heart-lung transplant by duration of follow-up.

(0.13MB).

In conclusion, this article presents the largest case series to date in Spain of paediatric patients with RCM, an infrequent disease in children with a very poor prognosis and a 5-year overall survival/transplant-free survival of 20%. Placement of a pacemaker or implantable cardioverter defibrillator for primary prevention should be contemplated in the early stages due to the high risk of arrhythmias, including atrioventricular block or sudden death.1 Pulmonary hypertension is a frequent complication that may contraindicate heart transplant, so early performance of heart transplant should be considered soon after detection of PHT, and also on account of the poor prognosis and lack of treatments. In patients with high PVRIs, ventricular support may be considered before transplantation. Due to the high incidence of complications and poor prognosis of RCM, it is particularly important to refer patients early for diagnosis and follow-up to highly specialised centres with paediatric arrhythmia and heart failure units that can also perform paediatric heart transplants.

References
[1]
M.A. Walsh, M.A. Grenier, J.L. Jefferies, J.A. Towbin, A. Lorts, R.J. Czosek.
Conduction abnormalities in pediatric patients with restrictive cardiomyopathy.
Circ Heart Fail., 5 (2012), pp. 267-273
[2]
S.W. Denfield, S.A. Webber.
Restrictive cardiomyopathy in childhood.
Heart Fail Clin., 6 (2010), pp. 445-452
[3]
J.P. Kaski, P. Syrris, M. Burch, M.-T. Tomé-Esteban, M. Fenton, M. Christiansen, et al.
Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes.
Heart., 94 (2008), pp. 1478-1484
[4]
S.A. Webber, S.E. Lipshultz, L.A. Sleeper, M. Lu, J.D. Wilkinson, L.J. Addonizio, et al.
Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the pediatric cardiomyopathy registry.
Circulation., 126 (2012), pp. 1237-1244
[5]
S.M. Rivenes, D.L. Kearney, E.O.B. Smith, J.A. Towbin, S.W. Denfield.
Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy.
Circulation., 102 (2000), pp. 876-882
[6]
F. Gran, D.C. Albert, A. Moreno.
Schistosomiasis and tropical endomyocardial fibrosis with pulmonary hypertension.
Rev Esp Cardiol., 64 (2011), pp. 713

Please cite this article as: Brunet-Garcia L, Roses-Noguer F, Betrián P, Balcells J, Gran F. Miocardiopatía restrictiva: la importancia de su diagnóstico precoz. An Pediatr (Barc). 2021;95:368–370.

Copyright © 2021. Asociación Española de Pediatría
Idiomas
Anales de Pediatría (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?